PortViewPortView
Filana Therapeutics logo

Filana Therapeutics (FLNA) Stock Analysis

NASDAQHealthcareBiotechnology

$0.82-4.12%
1-year price historyRange $0.83 – $2.45
52-week range$0.82
$0.82$4.98

What Filana Therapeutics does

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Key metrics

Market cap
$39.71M
P/E (TTM)
-0.94
EPS (TTM)
$-0.87
Beta
-0.69
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$1.03
200-day avg
$1.75
52-week high
$4.98
52-week low
$0.82
CEO
Richard Jon Barry

ETFs linked to FLNA

Broad-market and Healthcare sector ETFs an investor holding Filana Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how FLNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze FLNA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Filana Therapeutics?
Filana Therapeutics trades under the ticker FLNA on NASDAQ.
Which exchange is FLNA listed on?
FLNA is listed on NASDAQ.
What sector does Filana Therapeutics operate in?
Filana Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze FLNA in a portfolio?
PortView shows FLNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.